September 22, 2025 8:29am
Of “massive dispersion trades by big pod shops. The difference between the implied volatility for single names and for the index is near the highest level it ever gets. …We’re long index vol, short single name volume.” < Eifert, QVR Advisors>
News: Intellia Therapeutics (NTLA pre-open +$0.10) and Ionis Pharmaceuticals (IONS pre-open +$0.99 or +1.62%) <see below>
Pre-Open Signals: 3 Positive and 6 Negative
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
News: Intellia Therapeutics (NTLA) long-term data from the ongoing P1 trial of investigational nex-z for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) 9/25-26. This presentation will include ATTRv-PN disease-relevant measures, including up to 3 years of patient follow-up. Ionis Pharmaceuticals (IONS) positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments.
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My idea generation derives from a 35-year screening process, bears every metric on the covered sector that I know like the palm of my hand and what I generate for like-minded investors with whom I share suggestions.
Prepping for the end of September as Q3 is coming to a close – 7 sessions to go
Last Friday night’s … RMi Closing Bell: Sinking and Shrinking … https://www.regmedinvestors.com/articles/14115
RMi Research Note: Harvard Apparatus GT (OTCQB): Who is wasting lipstick on this pig? … https://www.regmedinvestors.com/articles/13812
Monday: The pre-open Dow futures are DOWN -0.38% or (-175 points), the S&P futures are DOWN -0.35% or (-24 points) and the Nasdaq futures are DOWN -0.39% or (-89 points)
- Futures are weak with falling action on Monday morning. 9/22
- European stocks were slightly lower with most sectors and major bourses in negative territory,
- Mixed market action in the Asia Pacific region
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
- Friday: The Dow closed UP +172.856 points or +0.37%, the S&P closed UP +32.40 points or +0.49% while the Nasdaq closed UP +160.751 points or +0.72%
- Thursday: The Dow closed UP +124.10 points or +0.27%, the S&P closed UP +31.61 points or +0.48% while the Nasdaq closed UP +209.399 points or +0.94%
- Wednesday: The Dow closed UP +260.42 points or +0.57%, the S&P closed DOWN -6.41 points or -0.10% while the Nasdaq closed DOWN -72.63 points or -0.33%
- Tuesday: The Dow closed DOWN -125.55 points or -0.27%, the S&P closed DOWN -8.52 points or -0.13% while the Nasdaq closed DOWN -14.79 points or -0.07%
- Monday: The Dow closed UP +49.23 points or +0.11%, the S&P closed UP +30.99 points or +0.47% while the Nasdaq closed UP +207.647 points or +0.94%
- Last week to date: The Dow is up +1%, the S&P 500 +1.2% and the Nasdaq +2.2%.
Economic Data Docket: 4 Fed Presidents nobody wants to hear from and 1 governor (Miran)to listen to
Q3 – September, 1 holiday, 7 negative and 7 positive closes
- August - 11 negative and 9 positive closes
- July – 1 market holiday, 13 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
- I see red after a econs will reveal their downing trend as September continues to close to the Q, along with the usual ups, downs and just plain uncertainties
A long with:
Alnylam Pharmaceuticals (ALNY) closed up +$1.39 after Thursday’s +$0.45 and Wednesday’s -$9.51 with a negative -$2.41 or -0.53% pre-open
Mesoblast (MESO) closed up +$1.26 with a negative -$0.27 or -1.59% pre-market
Vertex Pharmaceuticals (VRTX) closed down -$3.99 after Thursday’s -$0.04, Wednesday’s -$4.21, Tuesday’s -$1.85 and last Monday’s -$1.12 with a negative -$0.44 or -0.11% pre-open
Intellia Therapeutics (NTLA) closed down -$0.52 after Thursday’s +$3.70, Wednesday’s +$0.14, Tuesday’s +$0.70 and last Monday’s +$0.15 with a positive +$0.09 or +0.13% pre-open
CRISPR Therapeutics (CRSP) closed down -$0.62 after Thursday’s +3.87, Wednesday’s -$2.12, Tuesday’s +$3.35 and last Monday’s +$1.58 with a negative -$0.33 or -0.53% pre-open
BioNTech SE (BNTX) closed down -$0.09 after Thursday’s -$1.84, Wednesday’s -$1.11, Tuesday’s +$1.3 and last Monday’s +$1.14 with a positive +$0.15 or +0.16% pre-open
Moderna (MRNA) closed up +$0.45 after Wednesday’s +$0.16, Tuesday’s +$0.96, Monday’s +$0.37 and last Friday’s -$1.88 with a negative -$0.24 or +0.95% pre-open
The BOTTOM LINE: “It’s always darkest before the pitch dark” …
U.S. stock index futures inch lower on Monday after indexes rallied to record highs in the Friday’s session
Also, boosted by optimism around small-cap companies in the U.S., with the Russell 2000 hitting an intraday record high on Friday.
However, economic data is scheduled for release this week, including that for personal consumption expenditure - the Fed's preferred gauge of inflation - and gross domestic product seemingly will lower market expectations this wee.
Persistent econ challenges and alternating share pricing demand continues to hang over the cell and gene therapy sector.
- ″While September has historically delivered pullbacks, this year’s market has defied that pattern — climbing 35% since March with strong technical and fundamental tailwinds,” said Mark Hackett, chief market strategist at Nationwide. “Still, with the S&P 500 trading at 22x forward earnings and volatility suppressed, a period of consolidation or choppiness would be a normal and healthy development.” <CNBC>
September is in the front window: understand the “flow”
Last week:
- 9/19 – Friday closed negative with 7 positive, 33 negative and 0 flat
- 9/18 – Thursday closed positive with 33 positive, 6 negative and 1 flat
- 9/17 – Wednesday closed negative with 10 positive, 30 negative and 0 flat
- 9/16 – Tuesday closed positive with 29 positive, 9 negative and 2 flats
- 9/15 – Monday closed negative with 17 positive, 22 negative and 1 flat
September has historically delivered pullbacks, this year’s market has defied that pattern — climbing 35% since March with strong technical and fundamental tailwinds,
Q2 Earnings are in the rear-view mirror; we are about to start again … Q3!
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
Welcome to my world of defining the “grey’ in our universe!
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC):
The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.
